Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Automatically detect candlestick patterns on any chart

Read How
Market News Market Pulse Stocks News ETF News Crypto News

Gyre Therapeutics Inc.

Contributing Author

Recent Articles by Gyre Therapeutics Inc.

Aug-07
Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update GYRE GlobeNewswire
Jul-16
Gyre Therapeutics Appoints Three New Members to its Board of Directors GYRE GYRE -5.76% GlobeNewswire
May-12
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment GYRE GlobeNewswire
May-07
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update GYRE -12.06% GlobeNewswire
May-04
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company GYRE GlobeNewswire
Mar-17
Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment GYRE GlobeNewswire
Mar-12
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update GYRE -6.30% GlobeNewswire
Jan-05
Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting GYRE +16.30% GlobeNewswire
Nov-07
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update GYRE GlobeNewswire
Oct-15
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis GYRE +10.74% GlobeNewswire
Oct-14
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD-The Liver Meeting 2025 GYRE GlobeNewswire
Sep-05
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference GYRE GlobeNewswire
Aug-22
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors GYRE +8.34% GlobeNewswire
Aug-11
Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update GYRE GYRE +6.93% GlobeNewswire
Jun-10
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China GYRE +5.88% GlobeNewswire
May-29
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares GYRE GlobeNewswire
May-22
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock GYRE -22.57% GlobeNewswire
May-22
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock GYRE +8.10% GYRE -22.57% GlobeNewswire
May-22
Gyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China GYRE +8.10% GYRE -22.57% GlobeNewswire
May-09
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update GYRE GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)